Clinical Role - Specialty Pharmacy

Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.

FDA Approves Lasmiditan for Acute Treatment of Migraine With or Without Aura
Lasmiditan (Reyvow, Eli Lilly) resolved pain and most bothersome symptoms within 2 hours of treatment in patients with migraine.
FDA Grants Awarded to Rare Disease Research Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times. 
12 Difficult-to-Pronounce Drug Names, Part 3
This article is the third in a series on difficult to pronounce drug names.
Plitidepsin, Dexamethasone Combo Improves Progression-Free Survival in Heavily-Treated Multiple Myeloma
A phase 3 study assessed the efficacy and safety of plitidepsin (Aplidin) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.
Trending News Today: Certain Interventions Can Reduce Excessive Steroid Use in IBD
Top news of the day from across the health care landscape.
Study: Long-Term Dupilumab Safe and Effective in Adolescents with Atopic Dermatitis
Long-term treatment with dupilumab showed benefit in adolescents with atopic dermatitis comparable with the treatment’s effect in adults.
FDA Awards 12 Grants Towards Treatment of Rare Diseases
The grants were awarded through the Orphan Products Clinical Trials Grants Program, which is funded by Congress. 
New Research Shows Genetic Variants May Increase Leukemia Risk in Children with Down Syndrome
Researchers find 4 genetic variants that are strongly associated with the risk of acute lymphoblastic leukemia in children with Down syndrome.
Courier Service Delivering Health Care to Pharmacy Customers in Texas
Prescription medications and other health care items, including vitamins and supplements, eyewear, and natural medicine, such as pharmaceutical-grade CBD oil, is being delivered in the Dallas-Fort Worth (DFW) area with service to homes and offices.
Ramucirumab, Erlotinib Combo a Promising First-line EGFR-Mutated NSCLC Treatment
Ramucirumab (Cyramza) in combination with erlotinib delayed disease progression in previously untreated patients with EGFR-mutated non-small cell lung cancer.
Advice for Growing a Health System Specialty Pharmacy
A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.
+ Load More